Inc. (‘NKCL’) announced on the 21st that it had signed an MOU for mutual
cooperation and partnership with China's Heilongjiang Yiduoyi Biotechnology Co.,
Ltd. (‘YIDUOYI BIO’) to develop the Chinese market in the NK cell and
YIDUOYI BIO is
an affiliate in charge of the bio business to commercialize the business
agreement with NKCL Bio Group., newly established by China Endless Experience
NKCL Bio Group Inc. is a company that builds
an automatic culture system based on NK cell-related culture technology and
develops a full-fledged immunotherapy-related program. Shin Dong-Hwa, CEO of
NKCL, has announced through the media his ambition to enter into the Chinese
market as a core business of NKCL in 2022.
As the immunity-related market is expected to grow explosively in the
future due to the recent COVID-19 pandemic, YIDUOYI BIO in China had announced its
intention to sign a partnership for the development of the immune-related
market in China to respond more quickly to the Chinese market, which expedited the
technical cooperation or commercialization, the MOU contains practical and
permanent cooperation, including establishment of NK Human Immunotherapy Center,
NK cell automatic culture center and anti-aging center in the China, NKCL Immune Bakery chain business, Nurturing
excellent human resources in the bio field through industry-university
cooperation between Korea and China in the NK cell field, etc.
Endless Experience Co., Ltd. is planning to advance into China more quickly
with biotechnology-based services and products owned by NKCL based on the
so-called green pathway policy, which is called China's fast track policy. The
Green Passage Policy is a policy that grants the benefits of greatly easing the
existing complex licensing and customs procedures for companies, services, and
products of a certain level and scale in order to stimulate external economic
exchange and lead the development of high-tech industries. It can be said that
it is the result of being recognized for excellence in cell culture technology
and related services and products of NKCL.
Experience Co., Ltd., the parent company of YIDUOYI BIO, operates cord blood
stem cell treatment business, cord blood stem cell banking (storage) business,
bio cosmetics, and bio health functional food distribution business as its main
businesses. Running a marketing affiliate with the largest number of
influencers (Wang Hong) in China, it is evaluated as a specialized company that
is growing a new influence beyond a simple bio company.
MOU, the two companies plan to conduct joint marketing by actively utilizing
each company's technological prowess and brand power, and aggressively expand
the cell therapy business area in China in the future.
An official of
NKCL has said, "We expect that NKCL's entry into the Chinese business,
which has been temporarily suspended due to COVID-19, will be resumed based on
the Chinese partnership with YIDUOYI BIO."
order to advance into the global market, NKCL Bio Group is pushing to advance
into Dubai, Japan, the Philippines, and Myanmar in addition to China.
In order to
prevent the spread of COVID-19, this agreement was conducted in writing without
a separate agreement ceremony.